We are leading innovative science with the use of immunotherapies in earlier stages of cancer, especially for patients whose tumors could be removed by surgery. We believe that exploring the use of immunotherapy in earlier stages of cancer is important because of its potential to help prevent recurrence and address unmet needs as we work towards a cure for patients.
 

We have helped advance the treatment of gastrointestinal cancers including esophageal cancer, gastric, gastroesophageal junction, hepatocellular carcinoma (liver) and colorectal cancer through an understanding of the needs that still remain for patients.

Our portfolio and pipeline for genitourinary cancers spans multiple tumor types including bladder, kidney, as well as prostate*. We are exploring immunotherapies and targeted agents across multiple stages of cancer with the goal of helping address the unique needs of GU cancer patients.

* _{^{Pipeline only.}}

By harnessing the power of immunotherapy, we have helped transform the melanoma treatment landscape over the last decade and helped improve survival rates for patients. Today, we continue our research in both early and advanced stages of cancer to further advance the science.
 

We have helped redefine the treatment landscape for thoracic cancers and helped extend survival outcomes for patients. With both targeted medicines and immunotherapies, we aim to provide patients with safe and effective treatment options.

Breast cancer is the most frequently diagnosed cancer worldwide. We are researching novel immunotherapy treatment approaches and combinations for people living with breast, ovarian, and cervical cancers.